Bharat Biotech’s Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee (SEC) of the Indian drug regulator. The expert panel has approved the trial data, which was conducted on 25,800 subjects, as per reports.